{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:24:06Z","timestamp":1791357846671,"version":"4.3.1"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Co., Ltd. (KK)."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Erythropoiesis-stimulating agent (ESA) resistance is reported in approximately 10% of patients on hemodialysis and is a risk factor for mortality. The BRIGHTEN study conducted on 1,724 non-dialysis patients with chronic kidney disease (CKD) reported an ESA resistance prevalence of 13.3% and was associated with a risk factor for poor cardiovascular and renal prognoses. ESA resistance at 12 weeks after ESA administration can also indicate renal prognoses; however, a single-point estimate is insufficient because ESA resistance increases with CKD progression. We used the BRIGHTEN data for a sub-analysis and found that the ESA resistance index (ERI) (darbepoetin alpha dose\/hemoglobin level) transition pattern might be more appropriate for predicting renal prognoses than an initial single-point ERI value. This BRIGHTEN study sub-analysis included 1,625 patients with complete data, comprising 518 dialysis initiations and 18 renal transplants, with a mean follow-up of 1.79 years. The relationship between disease progression and ESA resistance was analyzed using the joint latent class model of longitudinal and time-to-event data. The Kaplan\u2013Meier method was used to estimate the cumulative incidence for the three classes according to the transition pattern of the ERIs. The patient background characteristics in each class were compared. The ERI transition pattern was classified into 3 classes: ERI unchanged, Class A (1,237 patients); moderately increased, Class B (274 patients); and rapidly increased, Class C (114 patients). Class C showed a significantly worse renal survival curve than the other groups, while Class B showed an intermediate survival curve (P\u2009&lt;\u20090.0001). The median renal survival times were 1.09 and 0.61 years in Classes B and C, respectively. Patients in Classes B and C were significantly more often male and had diabetic nephropathy, smoking, hypertension, and more proteinuria than those in Class A. Rapidly increasing ESA resistance patterns predict poor renal prognoses in patients with non-dialysis CKD.<\/jats:p>","DOI":"10.1371\/journal.pone.0325616","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:28:17Z","timestamp":1763749697000},"page":"e0325616","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rapid increase in erythropoiesis-stimulating agent resistance is a risk factor for poor renal prognosis in patients with chronic kidney disease pre-dialysis: A BRIGHTEN study sub-analysis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1934-9133","authenticated-orcid":true,"given":"Shinya","family":"Kawamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kagimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"7","key":"pone.0325616.ref001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236132","article-title":"Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB)","volume":"15","author":"T Sofue","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"pone.0325616.ref002","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s10157-010-0396-7","article-title":"Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study","volume":"15","author":"T Akizawa","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"pone.0325616.ref003","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2016.05.031","article-title":"Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients","volume":"68","author":"L Jiacong","year":"2016","journal-title":"AJKD"},{"issue":"3","key":"pone.0325616.ref004","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ndt\/gfl716","article-title":"Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients","volume":"22","author":"J Rossert","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0325616.ref005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41100-021-00332-0","article-title":"Hyporesponsiveness to long-acting erythropoiesis-stimulating agent is related to the risk of cardiovascular disease and death in Japanese patients on chronic hemodialysis: observational cohort study","volume":"7","author":"K Tanaka","year":"2021","journal-title":"Ren Replace Ther"},{"key":"pone.0325616.ref006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000496634","article-title":"Resistance to Erythropoiesis-Stimulating Agents in Pre-Dialysis and Post-Dialysis Mortality in Japanese Incident Hemodialysis Patients","volume":"47","author":"T Hayashi","year":"2019","journal-title":"Blood Purif"},{"issue":"5","key":"pone.0325616.ref007","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2215\/CJN.08900719","article-title":"Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial","volume":"15","author":"T Hayashi","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"pone.0325616.ref008","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10157-020-01969-7","article-title":"Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan","volume":"25","author":"T Hayashi","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"pone.0325616.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277921","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study","volume":"17","author":"I Narita","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0325616.ref010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41100-018-0145-z","article-title":"Lower Hb at the initiation of dialysis does not adversely affect 1-year mortality rate","volume":"4","author":"S Kawamoto","year":"2018","journal-title":"Ren Replace Ther"},{"issue":"2","key":"pone.0325616.ref011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v078.i02","article-title":"Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: The R Package lcmm","volume":"78","author":"C Proust-Lima","year":"2017","journal-title":"J Stat Soft"},{"issue":"1","key":"pone.0325616.ref012","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11255-013-0494-z","article-title":"Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study","volume":"46","author":"T Ogawa","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"pone.0325616.ref013","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.ajkd.2011.07.014","article-title":"Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan","volume":"59","author":"S Fukuma","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"pone.0325616.ref014","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000358215","article-title":"Erythropoietin Resistance Index and the All-Cause Mortality of Chronic Hemodialysis Patients","volume":"37","author":"M Okazaki","year":"2014","journal-title":"Blood Purif"},{"issue":"2","key":"pone.0325616.ref015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40620-014-0121-9","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study","volume":"28","author":"R Eriguchi","year":"2015","journal-title":"J Nephrol"},{"key":"pone.0325616.ref016","first-page":"62900","article-title":"Association between multimorbidity and kidney function among patients with non-dialysis-dependent CKD","author":"S Tanaka","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"pone.0325616.ref017","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10157-022-02227-8","article-title":"Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study","volume":"26","author":"FKR Study Collaboration Group","year":"2022","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"pone.0325616.ref018","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1093\/ndt\/gfs007","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients","volume":"27","author":"R Minutolo","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"pone.0325616.ref019","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ackd.2008.12.004","article-title":"Hyporesponsiveness to erythropoietin: causes and management","volume":"16","author":"J Elliott","year":"2009","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"pone.0325616.ref020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0272-6386(03)00915-6","article-title":"Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients","volume":"42","author":"K Kalantar-Zadeh","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"pone.0325616.ref021","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2337\/diacare.24.3.495","article-title":"Anemia with erythropoietin deficiency occurs early in diabetic nephropathy","volume":"24","author":"DR Bosman","year":"2001","journal-title":"Diabetes Care"},{"issue":"4","key":"pone.0325616.ref022","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archinte.165.4.466","article-title":"Anemia with impaired erythropoietin response in diabetic patients","volume":"165","author":"MC Thomas","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"pone.0325616.ref023","doi-asserted-by":"crossref","first-page":"14871","DOI":"10.1038\/s41598-019-51207-8","article-title":"Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study","volume":"9","author":"Y Fujita","year":"2019","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:28:23Z","timestamp":1763749703000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325616"}},"subtitle":[],"editor":[{"given":"Tarek Samy","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325616","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}